Investment analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
NAVB opened at $0.04 on Thursday. The stock has a market capitalization of $3.65 million, a P/E ratio of -0.61 and a beta of 1.14. The company’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.06. Navidea Biopharmaceuticals has a 52-week low of $0.02 and a 52-week high of $0.33.
Hedge Funds Weigh In On Navidea Biopharmaceuticals
A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. State Street Corp raised its position in shares of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) by 1,631.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 412,743 shares of the company’s stock after purchasing an additional 388,900 shares during the quarter. State Street Corp owned 1.18% of Navidea Biopharmaceuticals worth $38,000 as of its most recent SEC filing. 0.01% of the stock is currently owned by institutional investors and hedge funds.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- How to Evaluate a Stock Before Buying
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is the S&P 500 and How It is Distinct from Other Indexes
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
